Piper Sandler Stands by Overweight Rating on Nektar Therapeutics as Key Data Approaches
Piper Sandler has reiterated an Overweight rating on Nektar Therapeutics (NKTR) with a $105 price target, citing strong induction data for REZPEG and ample liquidity to support clinical programs. The firm flagged durability of response and regulatory endpoints as primary considerations ahead of maintenance topline results anticipated in the first q…